Loading
Latest filing published 27 Dec 2021 for Sorrento Therapeutics, Inc., €16k.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Kim Janda, listed as board member, appears in our data through filings on Sorrento Therapeutics, Inc. shares, published by SEC (Form 4). In total, 10 filings cover trades dated from 3 February 2017 to 27 December 2021.
In open-market terms, that means 1 purchase worth €14k on one side and 4 sales worth €372k on the other. Taken together, the sales exceed the purchases by €357k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 5 option exercises. 2021 to date brings no purchases and 4 sales.
Most recently, on 27 December 2021, the filings show an open-market sale worth €16k in Sorrento Therapeutics, Inc. The last insider purchase was made public on 3 February 2017, 3,550 days ago. Typically, a trade is published a median of 1 day after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
10 of 10 declarations